Cytopathology

Interpace Diagnostics Announces Publication of New Data on Thyroid Test Utility

Retrieved on: 
Monday, November 4, 2019
Thyroid disease, Branches of biology, Glands, Anatomy, RTT, Thyroid cancer, Thyroid nodule, Cytopathology, Thyroid, Cancer, Pathology, Noninvasive follicular thyroid neoplasm with papillary-like nuclear features

The most recent article was published in Diagnostic Cytopathology in a paper called Incremental Utility of Expanded Mutation Panel When Used in Combination with MicroRNA Classification in Indeterminate Thyroid Nodules.

Key Points: 
  • The most recent article was published in Diagnostic Cytopathology in a paper called Incremental Utility of Expanded Mutation Panel When Used in Combination with MicroRNA Classification in Indeterminate Thyroid Nodules.
  • The study concludes that expansion of the panel increases detection of mutations and fusions strongly associated with malignancy and aggressive thyroid cancer, increasing the panels utility in surgical decision making.
  • In addition, Interpaces pathologist, Dr. Tina Narick contributed to a chapter entitled Application of Molecular Tests in Indeterminate Thyroid FNA in the Atlas of Thyroid Cytopathology on Liquid-Based Preparations.
  • ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules.

Global Small Cell Lung Cancer Markets, Pipeline, Innovations, Key Players & Deals (2014-2024)

Retrieved on: 
Wednesday, October 30, 2019
Clinical medicine, Medicine, Antineoplastic drugs, Cancer treatments, Carcinoma, Cytopathology, Small-cell carcinoma, Lung cancer, Chemotherapy, SCLC, Cancer, Targeted therapy

Dublin, Oct. 30, 2019 (GLOBE NEWSWIRE) -- The "Frontier Pharma - Small Cell Lung Cancer: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Dublin, Oct. 30, 2019 (GLOBE NEWSWIRE) -- The "Frontier Pharma - Small Cell Lung Cancer: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease" report has been added to ResearchAndMarkets.com's offering.
  • Initially considered a curable disease due to substantial sensitivity to chemotherapy, small cell lung cancer (SCLC) remains a fatal disease with a poor outcome, with the majority of patients surviving one year or less after diagnosis.
  • The recent approval of targeted and immuno-therapies for SCLC will generate a new maintenance setting following chemotherapy in SCLC.
  • Recognize commercial opportunities by identifying first-in-class pipeline programs for SCLC that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for first-in-class SCLC programs.

Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent

Retrieved on: 
Wednesday, October 16, 2019
Cancer, Lung cancer, Clinical medicine, Neoplasms, Cancer treatments, Carcinoma, Cytopathology, RTT, Small-cell carcinoma, Non-small-cell lung carcinoma, Chemotherapy, Combined small-cell lung carcinoma

Management plans to expand its ongoing clinical myelopreservation trial to include two additional cohorts: an expansion cohort in small-cell lung cancer patients and a cohort in non-small-cell lung cancer patients.

Key Points: 
  • Management plans to expand its ongoing clinical myelopreservation trial to include two additional cohorts: an expansion cohort in small-cell lung cancer patients and a cohort in non-small-cell lung cancer patients.
  • Company expects to present key findings of the phase 1b portion of this myelopreservation trial in the 2nd quarter of 2020.
  • Every year, millions of cancer patients undergo chemotherapy with the hope of prolonging their lives or being cured from a deadly disease.
  • Although this first myelopreservation trial for ALRN-6924 is in SCLC patients treated with topotecan, we plan to develop ALRN-6924 as a tumor type-agnostic and chemotherapy-agnostic myelopreservation drug.

KEYNOTE-024 Three-Year Survival Update: Pembrolizumab Effective as First-Line Therapy for Advanced Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, September 10, 2019
Clinical medicine, Medicine, Antineoplastic drugs, Cancer treatments, Carcinoma, Cytopathology, Small-cell carcinoma, Non-small-cell lung carcinoma, Cancer, Pembrolizumab, Lung cancer, Chemotherapy

The 36-month overall survival rate was 43.7 percent in the pembrolizumab arm vs 24.9 percent in the chemotherapy arm.

Key Points: 
  • The 36-month overall survival rate was 43.7 percent in the pembrolizumab arm vs 24.9 percent in the chemotherapy arm.
  • Historically, outcomes for advanced non-small cell lung cancer have been poor, with five-year survival rates less than five percent with conventional chemotherapy.
  • "We shared our online survey with lung cancer advocates and patients with lung cancer," Dr. Baird said.
  • The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies.

KEYNOTE-024 Three-Year Survival Update: Pembrolizumab Effective as First-Line Therapy for Advanced Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, September 10, 2019
Clinical medicine, Medicine, Antineoplastic drugs, Cancer treatments, Carcinoma, Cytopathology, Small-cell carcinoma, Non-small-cell lung carcinoma, Cancer, Pembrolizumab, Lung cancer, Chemotherapy

The 36-month overall survival rate was 43.7 percent in the pembrolizumab arm vs 24.9 percent in the chemotherapy arm.

Key Points: 
  • The 36-month overall survival rate was 43.7 percent in the pembrolizumab arm vs 24.9 percent in the chemotherapy arm.
  • Historically, outcomes for advanced non-small cell lung cancer have been poor, with five-year survival rates less than five percent with conventional chemotherapy.
  • "We shared our online survey with lung cancer advocates and patients with lung cancer," Dr. Baird said.
  • The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies.

ORYZON’s Iadademstat Shows Efficacy Signs in Relapsed SCLC

Retrieved on: 
Monday, September 9, 2019
Cancer, Neoplasms, Lung cancer, Clinical medicine, Carcinoma, Cytopathology, Small-cell carcinoma

The company will present a poster, at the IASLC 20th World Conference on Lung Cancer (WCLC), being held in Barcelona, Spain, entitled Iadademstat shows preliminary efficacy signals in relapsed ED-SCLC patients: A case report within CLEPSIDRA, a Phase II trial of iadademstat in combination with platinum-etoposide in biomarker-positive patients.

Key Points: 
  • The company will present a poster, at the IASLC 20th World Conference on Lung Cancer (WCLC), being held in Barcelona, Spain, entitled Iadademstat shows preliminary efficacy signals in relapsed ED-SCLC patients: A case report within CLEPSIDRA, a Phase II trial of iadademstat in combination with platinum-etoposide in biomarker-positive patients.
  • CLEPSIDRA ("A Combination trial of LSD1 and Etop-Platinum in Small Cell Lung Cancer in Biomarker-ID Relapsed pAtients) is a Phase IIa trial of iadademstat, being conducted in several hospitals in Spain.
  • A first Phase I/IIa clinical trial with iadademstat in refractory and relapsed acute leukemia patients demonstrated the safety and good tolerability of the drug and preliminary signs of antileukemic activity, including a CRi.
  • Oryzons securities may not be offered or sold in the United States absent registration or an exemption from registration.

Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 14, 2019
Carcinoma, Cytopathology, Lung cancer, Small-cell carcinoma, Huntingtons, Cancer, Health, Causes of death, Epidemiology

Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected in the second half of 2019

Key Points: 
  • Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected in the second half of 2019
    ROCHESTER, N.Y., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntingtons disease, today announced financial results for the second quarter ended June 30, 2019 and provided a corporate update.
  • The Companys SIGNAL trial evaluating pepinemab for the treatment of Huntingtons disease is ongoing, with topline data expected in the second half of 2020.
  • Revenue for the three months ended June 30, 2019 was $25,000 as compared to $126,000 for the comparable period in 2018.
  • Revenue recognized during the second quarter of 2019 was derived from the collaboration agreement with Surface Oncology.

Worldwide Histology & Cytology Market Insights & Forecasts (2016-2026): A $27.9 Billion Industry Opportunity by 2026

Retrieved on: 
Friday, August 9, 2019
Infectious causes of cancer, Gynaecological cancer, Cytopathology

The global histology and cytology market is set to grow from US$ 8,928.1 million in 2017 to US$ 27,949.9 million by 2026 at a CAGR of 13.6% from 2018 to 2026.

Key Points: 
  • The global histology and cytology market is set to grow from US$ 8,928.1 million in 2017 to US$ 27,949.9 million by 2026 at a CAGR of 13.6% from 2018 to 2026.
  • Increasing public health awareness and sophistication of technology pertaining to early screening and diagnosis promote the histology and cytology market growth.
  • Cytology examination procedures are leading the examination segment for histology and cytology market.
  • North America presently holds a 35% market share and is dominating the regional segment for histology and cytology market.

United States Small Cell Lung Cancer Market Report 2019: Treatment, Pipeline, Epidemiology, Key Products, Valuations, Drug Sales and Market Shares - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 11, 2019
Professional services, Consulting, Cancer, Clinical medicine, Medicine, Cancer treatments, Carcinoma, Cytopathology, Small-cell carcinoma, Lung cancer, Chemotherapy, Epidemiology of cancer, Savolitinib, Cancer immunotherapy

The "US Small Cell Lung Cancer Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Small Cell Lung Cancer Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.
  • US Small Cell Lung Cancer Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Small Cell Lung Cancer pipeline products, Small Cell Lung Cancer epidemiology, Small Cell Lung Cancer market valuations and forecast, Small Cell Lung Cancer drugs sales and competitive landscape in the US.
  • Small Cell Lung Cancer pipeline: Find out the products in clinical trials for the treatment of Small Cell Lung Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Small Cell Lung Cancer epidemiology: Find out the number of patients diagnosed (prevalence) with Small Cell Lung Cancer in the US
    Small Cell Lung Cancer drugs: Identify key products marketed and prescribed for Small Cell Lung Cancer in the US, including trade name, molecule name, and company
    Small Cell Lung Cancer drugs sales: Find out the sales revenues of Small Cell Lung Cancer drugs in the US
    Small Cell Lung Cancer market valuations: Find out the market size for Small Cell Lung Cancer drugs in 2018 in the US.
  • Find out how the market advanced from 2014 and forecast to 2024
    Small Cell Lung Cancer drugs market share: Find out the market shares for key Small Cell Lung Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Small Cell Lung Cancer products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190711005340/en/

United States Non-Small Cell Lung Cancer Market and Competitive Landscape Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 1, 2019
Pharmaceutical, Health, Oncology, Cancer, Clinical medicine, Medicine, Lung cancer, Cancer treatments, Carcinoma, Cytopathology, Small-cell carcinoma, Chemotherapy, Epidemiology of cancer, Savolitinib, Lorlatinib

The "US Non-Small Cell Lung Cancer Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Non-Small Cell Lung Cancer Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.
  • US Non-Small Cell Lung Cancer Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Non-Small Cell Lung Cancer pipeline products, Non-Small Cell Lung Cancer epidemiology, Non-Small Cell Lung Cancer market valuations and forecast, Non-Small Cell Lung Cancer drugs sales and competitive landscape in the US.
  • Non-Small Cell Lung Cancer pipeline: Find out the products in clinical trials for the treatment of Non-Small Cell Lung Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Non-Small Cell Lung Cancer epidemiology: Find out the number of patients diagnosed (prevalence) with Non-Small Cell Lung Cancer in the US
    Non-Small Cell Lung Cancer drugs: Identify key products marketed and prescribed for Non-Small Cell Lung Cancer in the US, including trade name, molecule name, and company
    Non-Small Cell Lung Cancer drugs sales: Find out the sales revenues of Non-Small Cell Lung Cancer drugs in the US
    Non-Small Cell Lung Cancer market valuations: Find out the market size for Non-Small Cell Lung Cancer drugs in 2018 in the US.
  • Find out how the market advanced from 2014 and forecast to 2024
    Non-Small Cell Lung Cancer drugs market share: Find out the market shares for key Non-Small Cell Lung Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Non-Small Cell Lung Cancer products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190701005406/en/